Diprop. de Betametasona+Sulf Gentamicina EMS indications
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous
Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
The intra-articular or soft tissue administration of Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
The intralesional administration of Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum.
Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia
Diprop. de Betametasona+Sulf Gentamicina EMS description
Each gram of Diprop. de Betametasona+Sulf Gentamicina EMS cream/ointment contains Betamethasone (Diprop. de Betametasona+Sulf Gentamicina EMS) dipropionate 640 mcg equivalent to Betamethasone (Diprop. de Betametasona+Sulf Gentamicina EMS) 500 mcg and Gentamicin (Diprop. de Betametasona+Sulf Gentamicina EMS) sulfate equivalent to Gentamicin (Diprop. de Betametasona+Sulf Gentamicina EMS) base 1 mg.
Diprop. de Betametasona+Sulf Gentamicina EMS cream is an oil-in-water emulsion. It contains mineral oil, white petrolatum and cetostearyl alcohol for its oil phase in emulsion base and chlorocresol as preservative.
Diprop. de Betametasona+Sulf Gentamicina EMS ointment contains white petrolatum as its excipient.
Diprop. de Betametasona+Sulf Gentamicina EMS dosage
A thin film of Diprop. de Betametasona+Sulf Gentamicina EMS should be applied to cover completely the affected area twice daily, in the morning and at night.
Frequency of application should be determined by the physician according to the severity of the condition. For some patients, adequate maintenance therapy may be achieved with less frequent application.
Duration of Treatment: Duration of therapy varies depending upon the extent and location of disease and patient response. However, if clinical improvement is not achieved by 3-4 weeks, diagnosis should be reviewed.
Diprop. de Betametasona+Sulf Gentamicina EMS interactions
Concurrent use of Phenobarbital, Phenytoin, rifampin or ephedrine may enhance the metabolism of corticosteroids, reducing their therapeutic effects.
Patients receiving both a corticosteroid an estrogen should be observed for excessive corticosteroid effects.
Concurrent use of corticosteroids with potassium-depleting diuretics may enhance
Hypokalemia with cardiac glycosides may enhance the possibility of arrhythmias or digitalis toxicity associated with hypokalemia. Corticosteroids may enhance the potassium depletion caused by amphotericin B. In all patients taking any of these drug therapy combinations, serum electrolyte determinations, particularly potassium levels should be monitored closely.
Concurrent use of corticosteroids with coumarin-type anticoagulants may increase or decrease the anticoagulant effects possibly requiring adjustment in dosage.
Combined effects of non-steroidal anti-inflammatory drugs or alcohol with glucocorticosteroids may result in an increased occurrence or increased severity of gastrointestinal ulceration.
Corticosteroids may decrease blood salicylate concentrations. Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Dosage adjustments of an antidiabetic drug may be necessary when corticosteroids are given to diabetics.
Concomitant glucocorticosteroid therapy may inhibit the response to somatotropin.
Laboratory test interactions: corticosteroids may affect the nitroblue tetrazolium test for bacterial infection and produce false negative results.
Diprop. de Betametasona+Sulf Gentamicina EMS side effects
Adverse reactions to Diprop. de Betametasona+Sulf Gentamicina EMS cream or ointment therapy have been reported very rarely and include hypersensitivity and skin discoloration.
Treatment with Gentamicin (Diprop. de Betametasona+Sulf Gentamicina EMS) has produced transient irritation (erythema and pruritus) that usually did not require discontinuance of treatment.
Reported adverse reactions with the use of topical corticosteroids, especially under occlusive dressings, include: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Diprop. de Betametasona+Sulf Gentamicina EMS contraindications
History of sensitivity reactions to Betamethasone (Diprop. de Betametasona+Sulf Gentamicina EMS), Gentamicin (Diprop. de Betametasona+Sulf Gentamicina EMS) or to any of the components of Diprop. de Betametasona+Sulf Gentamicina EMS.
Topical corticosteroids are contraindicated in vaccinia, varicella and tuberculosis of the skin.
Active ingredient matches for Diprop. de Betametasona+Sulf Gentamicina EMS:
Betamethasone/Gentamicin in Brazil.
List of Diprop. de Betametasona+Sulf Gentamicina EMS substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Diprop. de Betametasona+Sulf Gentamicina Teuto Bras (Brazil) | |
Diprosone G (Mexico) | |
Cream; Topical; Betamethasone Dipropionate 0.05%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Diprospan G (Chile) | |
Cream; Topical; Betamethasone Dipropionate 0.05%; Gentamicin Sulfate 0.1% (Essex) | |
Diprovate-G (India) | |
Diprovate-G Betamethasone dipropionate0.05 % w/w, Gentamicinsulphate 0.1 % w/w. CRM / 10g (Fulford) | $ 0.39 |
10g (Fulford) | $ 0.39 |
DIPROVATE-G cream 10g (Fulford) | $ 0.39 |
Duotrat (Brazil) | |
Durabetagent (Germany) | |
Egerian (Italy) | |
Eponix G (Pakistan) | |
EXEVATE G | |
EXEVATE G 0.05%/0.1% CREAM 1 tube / 20 GM cream each (Ochoa Laboratories Ltd) | $ 0.46 |
EXEVATE G CREAM 1 tube / 10 GM cream each (Ochoa Laboratories Ltd) | $ 0.46 |
Exevate G 0.05%/1% Cream (Ochoa Laboratories Ltd) | $ 0.46 |
Exevate G Cream (Ochoa Laboratories Ltd) | $ 0.46 |
Eyecalm (Taiwan) | |
Eyecalm 5 mL | |
Fidagenbeta (Italy) | |
Futusoa (Taiwan) | |
Futusoa 1 g | |
Futusoa 5 g | |
Futusoa 10 g | |
Futusoa 20 g | |
Futusoa 450 g | |
Futusoa 1 kg | |
Garabet (Venezuela) | |
Garabeta (Taiwan) | |
Garabeta 5 mL | |
Garamat (Greece) | |
Garamicina-V (Mexico) | |
Garasone (Bahrain, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Croatia (Hrvatska), Czech Republic, Dominican Republic, El Salvador, Guatemala, Honduras, Hong Kong, Indonesia, Malaysia, Malta, Nicaragua, Oman, Panama, Philippines, Romania, Singapore, Slovakia, Taiwan) | |
Liquid; Ophthalmic, Otic; Betamethasone Sodium Phosphate 1 mg; Gentamicin Sulfate 3 mg / ml (Mantecorp) | |
Ointment; Ophthalmic; Betamethasone Sodium Phosphate 1 mg; Gentamicin Sulfate 3 mg / g (Mantecorp) | |
Garasone 5 mL (Mantecorp) | $ 11.95 |
Garasone 3 g (Mantecorp) | $ 9.05 |
Garasone 3.5 g (Mantecorp) | |
Garasone 5 mL x 1's (Mantecorp) | $ 11.48 |
Garasone Oftalmico | |
Solution; Ophthalmic; Betamethasone Sodium Phosphate 0.1%; Gentamicin Sulfate 0.3% | |
GARTIC | |
GARTIC EAR DROPS 1 packet / 5 ML ear drop each (Admac Pharma Ltd) | $ 0.33 |
Gartic Ear Drop (Admac Pharma Ltd) | $ 0.33 |
GB (United States) | |
GB Topical Spray (United States) | |
Gelmicin (Mexico) | |
Cream; Topical; Betamethasone Dipropionate 0.05%; Clotrimazole 1%; Gentamicin Sulfate 0.1% (Collins) | |
GENCIN B | |
GENCIN B DROPS 1 packet / 10 ML drop each (Torque Pharmaceuticals Pvt Ltd) | $ 0.15 |
Gencin B Drop (Torque Pharmaceuticals Pvt Ltd) | $ 0.15 |
Genderon (Taiwan) | |
Genderon 5 mL | |
Genderon 10 mL | |
See 350 substitutes for Diprop. de Betametasona+Sulf Gentamicina EMS |
References
- DailyMed. "GENTAMICIN SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Diprop. de Betametasona+Sulf Gentamicina EMS are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Diprop. de Betametasona+Sulf Gentamicina EMS. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology